Neil Pegg
Directeur Technique/Scientifique/R&D chez CellCentric Ltd.
Profil
Neil Pegg is currently the Director & Chief Scientific Officer at CellCentric Ltd.
He previously worked as Chemistry Director at Piramed Ltd., Research Director at ReOx Ltd., Director-Discovery Chemistry at OSI Pharmaceuticals (UK) Ltd., and Research Leader at GSK Plc.
Dr. Pegg received his undergraduate degree from the University of Bristol and his doctorate from The University of Nottingham in 1987.
Postes actifs de Neil Pegg
| Sociétés | Poste | Début |
|---|---|---|
CellCentric Ltd.
 CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Neil Pegg
| Sociétés | Poste | Fin |
|---|---|---|
| OSI Pharmaceuticals (UK) Ltd. | Corporate Officer/Principal | - |
Piramed Ltd.
 Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
ReOx Ltd.
 ReOx Ltd. Pharmaceuticals: MajorHealth Technology ReOx Ltd. discovers and develops drugs. It provides novel treatments for disease by controlling the actvity of hypoxia inducible factor. The company was founded by Christopher W. Pugh, Patrick Maxwell, Peter J. Ratcliffe, and Christopher J. Schofield in June 2003 and is headquartered in Thame, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Formation de Neil Pegg
| The University of Nottingham | Doctorate Degree |
| University of Bristol | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
ReOx Ltd.
ReOx Ltd. Pharmaceuticals: MajorHealth Technology ReOx Ltd. discovers and develops drugs. It provides novel treatments for disease by controlling the actvity of hypoxia inducible factor. The company was founded by Christopher W. Pugh, Patrick Maxwell, Peter J. Ratcliffe, and Christopher J. Schofield in June 2003 and is headquartered in Thame, the United Kingdom. | Health Technology |
Piramed Ltd.
Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Commercial Services |
| OSI Pharmaceuticals (UK) Ltd. | |
CellCentric Ltd.
CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
